Objective: To determine the opinions of therapists about constraint-induced movement therapy (CIMT).
Method: A convenience sample of 92 therapists with at least 1 year of clinical experience working in outpatient and inpatient hospital and clinical neurorehabilitation settings was surveyed. Subjects completed a self-report questionnaire discerning their opinions of CIMT during their clinical staff meetings. The questionnaire described CIMT to participants using excerpts from a recently published trial of CIMT. Subjects then responded to various statements concerning their opinions of the protocol and supplied the rationale for their opinions.
Results: Seventy-five percent of participants reported that it would be very difficult or difficult to administer CIMT in their clinics, and 83% felt that most clinics would not have the resources to implement CIMT. Additionally, more than 61% of respondents stated that managed care payers were either somewhat unlikely or very unlikely to reimburse for CIMT, and no respondent believed that it was very likely that managed care would fund CIMT. Most respondents felt that patients would experience great difficulty with the clinical session and restrictive device durations. There were 78.3% of participants who were not aware that an efficacious modified CIMT regimen was available that could overcome the aforementioned challenges.
Conclusions: Findings were consistent with CIMT trials and surveys regarding client compliance difficulties and therapist misgivings. Findings argue for continued refinement of modified CIMT regimens as well as greater educational efforts regarding CIMT for therapists.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1310/tsr1903-268 | DOI Listing |
Lancet Neurol
February 2025
Department of Neurology, International University of Health and Welfare, Narita, Japan.
Background: Evidence from preclinical studies suggests that IL-6 signalling has the potential to modulate immunopathogenic mechanisms upstream of autoantibody effector mechanisms in patients with generalised myasthenia gravis. We aimed to assess the safety and efficacy of satralizumab, a humanised monoclonal antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis.
Methods: LUMINESCE was a randomised, double-blind, placebo-controlled, multicentre, phase 3 study at 105 sites, including hospitals and clinics, globally.
Healthcare (Basel)
January 2025
Allied Health Research Unit, St Vincent's Health Network Sydney, Darlinghurst, NSW 2010, Australia.
Constraint-induced movement therapy (CIMT) is an evidence-based intervention for arm recovery after acquired brain injury. Clinician knowledge, time and confidence in delivering CIMT are established barriers to the routine use of CIMT in practice. CIMT delivery via telehealth is one option to help overcome these barriers.
View Article and Find Full Text PDFMetabolites
January 2025
Diabetes, Obesity and Human Reproduction Research Group, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) & Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universidad de Alcalá, 28034 Madrid, Spain.
This study aimed to evaluate whether glycoprotein and lipoprotein lipidomics profiles could enhance a clinical predictive model for carotid subclinical atherosclerosis in patients with type 1 diabetes (T1D). Additionally, we assessed the influence of cardiac autonomic neuropathy (CAN) on these predictive models. We conducted a cross-sectional study including 256 patients with T1D.
View Article and Find Full Text PDFBrain Sci
January 2025
Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Background/aim: Currently, there are limited evidence-based protocols for improving upper extremity (UE) motor function after stroke. The Keys protocol, a distributed form of constraint-induced movement therapy (CIMT), delivers CIMT components in fewer hours per day over an extended period, fitting outpatient rehabilitation schedules and third-party payor models. This pilot study aimed to assess the effectiveness of the Keys protocol in enhancing UE capacity and performance poststroke.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
Department of Endocrine, The 900th Hospital of Joint Logistic Support Force, the Chinese People's Liberation Army (PLA), Fuzhou, China.
Objective: Type 2 diabetes mellitus (T2DM) is a major cause of atherosclerosis, as well as an independent risk factor of cardiovascular adverse events. We aimed to evaluate the association of serum Meteorin-like protein (Metrnl) level with carotid atherosclerosis as determined by carotid intima-media thickness (CIMT) status in subjects with T2DM.
Methods: This cross-sectional study included 83 T2DM subjects without pre-existing cardiovascular diseases.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!